Tawanda Gumbo, MD, is a physician scientist, rising to the rank of Professor of Medicine. Medical School was at the University of Zimbabwe, Residency in Internal Medicine at Case Western Reserve University, and Fellowship in Infectious Diseases at the Cleveland Clinic, in Cleveland, Ohio.

Dr. Gumbo developed several preclinical and clinical laboratory models for fungal, parasitic, bacterial and viral infections, the human immune system, and cancer. He has also developed several mathematical models for translation from the laboratory to patients in the area of therapeutics and quantitative translational pharmacology, and for characterizing disease progression and the immune system in patients based on next generation sequencing and other ‘omics.

He has received research funding for decades from the US NIH, and other private-public funders. Dr. Gumbo is the recipient of numerous awards. His research work has been used to identify optimal doses of the three currently licensed antifungal drugs called echinocandins, anti-TB compounds by the WHO Global TB Program and by national TB programs in numerous countries, the design of new anti-TB drug regimens for children and adults, treatment of non-tuberculous mycobacteria, and together with his team recently identified and characterized safe inhibitors of the fundamental physiologic pathway, sonic hedgehog signaling, and the role of inhibitory immune checkpoints in TB.

He holds several patents for diagnostics, and for monoclonal antibodies that bind to FCER1. Dr. Gumbo is also a published poet and novelist. He also writes the introduction chapter to anti-infective therapy chapter, and the treatment of mycobacterial infections chapter in Goodman & Gilman’s The Pharmacological Basis of Therapeutics, referred to as the “Bible of pharmacology. He has authored about 200 scientific publications on PubMed: VIEW HERE